Department of Pathology, Botucatu Medical School, São Paulo State University (Unesp), Botucatu, São Paulo, Brazil.
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
J Cell Physiol. 2023 Aug;238(8):1756-1767. doi: 10.1002/jcp.31084. Epub 2023 Jul 25.
EGFL7 is a proangiogenic factor. It has been widely described with having a vital role in tubulogenesis and regulation of angiogenesis, mainly during embryogenesis and organogenesis. It has been mainly associated with NOTCH pathway, but there are reports showing association with MAPK and integrin pathways. Given its association with angiogenesis and these other pathways, there are several studies associating EGFL7 with carcinogenesis. In fact, most of the studies have pointed to EGFL7 as an oncogene, and some of them suggest EGFL7 expression as a possible biomarker of prognosis or use for a patient's follow-up. Here, we review the molecular pathways which EGFL7 is associated and highlight several studies describing the role of EGFL7 in tumorigenesis, separated by tumor type. Besides its role on angiogenesis, EGFL7 may act in other pathways as oncogene, which makes it a possible biomarker and a candidate to targeted therapy.
EGFL7 是一种促血管生成因子。它在管状形成和血管生成的调节中起着至关重要的作用，主要在胚胎发生和器官发生期间，这一点已得到广泛描述。它主要与 NOTCH 途径相关，但也有报道表明它与 MAPK 和整合素途径相关。鉴于其与血管生成和这些其他途径的关联，有几项研究将 EGFL7 与癌症发生相关联。事实上，大多数研究都将 EGFL7 作为致癌基因，其中一些研究表明 EGFL7 表达可能是预后的生物标志物或用于患者随访。在这里，我们回顾了 EGFL7 相关的分子途径，并重点介绍了几项描述 EGFL7 在肿瘤发生中的作用的研究，按肿瘤类型进行了分类。除了在血管生成中的作用外，EGFL7 还可以作为致癌基因在其他途径中发挥作用，这使其成为一个潜在的生物标志物和靶向治疗的候选物。
